{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 have been linked to the most common familial form and some sporadic forms of PD. Many LRRK2 mutation carriers exhibit typical PD symptoms indistinguishable from idiopathic PD cases.",
          "judgment": "Yes",
          "reasoning": "The paper establishes a clear link between LRRK2 mutations and Parkinson's disease, implying a role in neuronal function and survival."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study investigates phosphorylation levels and 14-3-3 binding, which are relevant to LRRK2 regulation and cellular function.",
          "judgment": "Yes",
          "reasoning": "Phosphorylation and protein binding assays are relevant to understanding LRRK2 function and how mutations might disrupt its normal activity related to PD."
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study uses wild-type LRRK2 as a normal control and LRRK2-S935A as a negative control. Experiments were repeated multiple times.",
          "judgment": "Yes",
          "reasoning": "The study uses both normal/negative controls (wild-type LRRK2) and abnormal/positive/null (LRRK2-S935A, S935A prevents phosphorylation), and mentions repeats, satisfying the requirements for Sub-step 3a."
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study tested known pathogenic variants R1441G, Y1699C, and G2019S.",
          "judgment": "Yes",
          "reasoning": "The study included known pathogenic variants as controls."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The quantification of the signals was performed using LI-COR and Odyssey software and the data was analyzed by One-way ANOVA (** P<0.01).",
          "judgment": "No",
          "reasoning": "While statistical analysis (ANOVA) was performed, the paper does not provide sufficient statistical information to calculate OddsPath."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study included at least 3 pathogenic variant controls. R1441G, Y1699C, and G2019S.",
          "judgment": "Yes",
          "reasoning": "There are more than 11 total variants tested in the study."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "LRRK2 R1441G exhibits reduced phosphorylation of S935 and reduced 14-3-3 binding. The study used appropriate controls, known pathogenic variants and multiple replicates; however, the study doesn't calculate OddsPath, resulting in PS3_moderate."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 have been linked to the most common familial form and some sporadic forms of PD. Many LRRK2 mutation carriers exhibit typical PD symptoms indistinguishable from idiopathic PD cases.",
          "judgment": "Yes",
          "reasoning": "The paper establishes a clear link between LRRK2 mutations and Parkinson's disease, implying a role in neuronal function and survival."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study investigates phosphorylation levels and 14-3-3 binding, which are relevant to LRRK2 regulation and cellular function.",
          "judgment": "Yes",
          "reasoning": "Phosphorylation and protein binding assays are relevant to understanding LRRK2 function and how mutations might disrupt its normal activity related to PD."
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study uses wild-type LRRK2 as a normal control and LRRK2-S935A as a negative control. Experiments were repeated multiple times.",
          "judgment": "Yes",
          "reasoning": "The study uses both normal/negative controls (wild-type LRRK2) and abnormal/positive/null (LRRK2-S935A, S935A prevents phosphorylation), and mentions repeats, satisfying the requirements for Sub-step 3a."
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study tested known pathogenic variants R1441G, Y1699C, and G2019S.",
          "judgment": "Yes",
          "reasoning": "The study included known pathogenic variants as controls."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The quantification of the signals was performed using LI-COR and Odyssey software and the data was analyzed by One-way ANOVA (** P<0.01).",
          "judgment": "No",
          "reasoning": "While statistical analysis (ANOVA) was performed, the paper does not provide sufficient statistical information to calculate OddsPath."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study included at least 3 pathogenic variant controls. R1441G, Y1699C, and G2019S.",
          "judgment": "Yes",
          "reasoning": "There are more than 11 total variants tested in the study."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "LRRK2 Y1699C exhibits reduced phosphorylation of S935 and reduced 14-3-3 binding. The study used appropriate controls, known pathogenic variants and multiple replicates; however, the study doesn't calculate OddsPath, resulting in PS3_moderate."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 have been linked to the most common familial form and some sporadic forms of PD. Many LRRK2 mutation carriers exhibit typical PD symptoms indistinguishable from idiopathic PD cases.",
          "judgment": "Yes",
          "reasoning": "The paper establishes a clear link between LRRK2 mutations and Parkinson's disease, implying a role in neuronal function and survival."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study investigates phosphorylation levels and 14-3-3 binding, which are relevant to LRRK2 regulation and cellular function.",
          "judgment": "Yes",
          "reasoning": "Phosphorylation and protein binding assays are relevant to understanding LRRK2 function and how mutations might disrupt its normal activity related to PD."
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study uses wild-type LRRK2 as a normal control and LRRK2-S935A as a negative control. Experiments were repeated multiple times.",
          "judgment": "Yes",
          "reasoning": "The study uses both normal/negative controls (wild-type LRRK2) and abnormal/positive/null (LRRK2-S935A, S935A prevents phosphorylation), and mentions repeats, satisfying the requirements for Sub-step 3a."
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study tested known pathogenic variants R1441G, Y1699C, and G2019S.",
          "judgment": "Yes",
          "reasoning": "The study included known pathogenic variants as controls."
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The quantification of the signals was performed using LI-COR and Odyssey software and the data was analyzed by One-way ANOVA (** P<0.01).",
          "judgment": "No",
          "reasoning": "While statistical analysis (ANOVA) was performed, the paper does not provide sufficient statistical information to calculate OddsPath."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study included at least 3 pathogenic variant controls. R1441G, Y1699C, and G2019S.",
          "judgment": "Yes",
          "reasoning": "There are more than 11 total variants tested in the study."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "LRRK2 G2019S exhibits a modest reduction of S935 phosphorylation in brain tissue and also shows reduced 14-3-3 binding. The study used appropriate controls, known pathogenic variants and multiple replicates; however, the study doesn't calculate OddsPath, resulting in PS3_moderate."
    }
  ]
}
